SG11202008925VA - Inhibitors of micro-rna 22 - Google Patents
Inhibitors of micro-rna 22Info
- Publication number
- SG11202008925VA SG11202008925VA SG11202008925VA SG11202008925VA SG11202008925VA SG 11202008925V A SG11202008925V A SG 11202008925VA SG 11202008925V A SG11202008925V A SG 11202008925VA SG 11202008925V A SG11202008925V A SG 11202008925VA SG 11202008925V A SG11202008925V A SG 11202008925VA
- Authority
- SG
- Singapore
- Prior art keywords
- rna
- inhibitors
- micro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862642934P | 2018-03-14 | 2018-03-14 | |
| PCT/US2019/022351 WO2019178411A1 (en) | 2018-03-14 | 2019-03-14 | Inhibitors of micro-rna 22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202008925VA true SG11202008925VA (en) | 2020-10-29 |
Family
ID=67908026
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202008921YA SG11202008921YA (en) | 2018-03-14 | 2019-03-14 | Micro-rna and obesity |
| SG11202008925VA SG11202008925VA (en) | 2018-03-14 | 2019-03-14 | Inhibitors of micro-rna 22 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202008921YA SG11202008921YA (en) | 2018-03-14 | 2019-03-14 | Micro-rna and obesity |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11499152B2 (en) |
| EP (2) | EP3765619A4 (en) |
| JP (2) | JP2021518841A (en) |
| KR (2) | KR20200132920A (en) |
| CN (2) | CN112119159A (en) |
| AU (2) | AU2019234916A1 (en) |
| BR (2) | BR112020018705A2 (en) |
| CA (2) | CA3093572A1 (en) |
| RU (2) | RU2020132725A (en) |
| SG (2) | SG11202008921YA (en) |
| WO (2) | WO2019178410A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020018705A2 (en) | 2018-03-14 | 2021-01-05 | Beth Israel Deaconess Medical Center | MICROWAVE INHIBITORS 22 |
| CN110609142A (en) * | 2019-10-09 | 2019-12-24 | 广州医科大学附属第二医院 | Method for detecting binding capacity of peripheral blood FTO protein and self-regulation element and application |
| CN115029347B (en) * | 2022-05-11 | 2024-02-20 | 珠海中科先进技术研究院有限公司 | Molecular monitoring sequence for recognizing and regulating hepatic and renal cell fibrosis, recombinant plasmid and virus inhibition |
| EP4353823A1 (en) * | 2022-10-12 | 2024-04-17 | Resalis Therapeutics S.r.l. | Inhibitors of micro-rna 22 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5981505A (en) | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
| US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
| US5840710A (en) | 1994-12-09 | 1998-11-24 | Genzyme Corporation | Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules |
| US6217900B1 (en) | 1997-04-30 | 2001-04-17 | American Home Products Corporation | Vesicular complexes and methods of making and using the same |
| AU731909B2 (en) | 1997-07-01 | 2001-04-05 | Isis Pharmaceuticals, Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
| SK17432000A3 (en) | 1998-05-26 | 2001-07-10 | Icn Pharmaceuticals, Inc. | Novel nucleosides having bicyclic sugar moiety |
| US6838283B2 (en) | 1998-09-29 | 2005-01-04 | Isis Pharmaceuticals Inc. | Antisense modulation of survivin expression |
| US6693187B1 (en) | 2000-10-17 | 2004-02-17 | Lievre Cornu Llc | Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge |
| JP4868739B2 (en) | 2002-05-06 | 2012-02-01 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | Nucleic acid delivery methods |
| DK2302055T3 (en) * | 2004-11-12 | 2014-10-13 | Asuragen Inc | Methods and compositions involving miRNA and miRNA inhibitor molecules |
| US20070213292A1 (en) * | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
| JP2009519339A (en) * | 2005-12-12 | 2009-05-14 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | MicroRNAs that regulate myocyte proliferation and differentiation |
| AU2013254923A1 (en) * | 2006-04-03 | 2013-11-28 | Santaris Pharma A/S | Pharmaceutical compositions comprising anti-miRNA antisense oligonucleotide |
| DK2666859T3 (en) | 2006-04-03 | 2019-04-08 | Roche Innovation Ct Copenhagen As | PHARMACEUTICAL COMPOSITION CONTAINING ANTI-miRNA ANTISENSE OLIGONUCLEOTIDES |
| ES2463665T3 (en) * | 2007-10-04 | 2014-05-28 | Stella Aps | Combination treatment for the treatment of hepatitis C virus infection |
| WO2010120803A2 (en) * | 2009-04-13 | 2010-10-21 | Somagenics Inc. | Methods and compositions for detection of small rnas |
| NZ597078A (en) * | 2009-06-08 | 2013-11-29 | Miragen Therapeutics | CHEMICAL MODIFICATION MOTIFS FOR miRNA INHIBITORS AND MIMETICS |
| UY33807A (en) * | 2010-12-17 | 2012-07-31 | Sanofi Sa | miRNAs as indicators of tissue status or of diseases such as osteoarthritis |
| CA2832899A1 (en) | 2011-04-12 | 2012-10-18 | Beth Israel Deaconess Medical Center, Inc. | Micro-rna inhibitors and their uses in disease |
| WO2013125691A1 (en) * | 2012-02-23 | 2013-08-29 | 住友ベークライト株式会社 | Method for classifying test body fluid sample |
| US9034839B2 (en) | 2012-04-20 | 2015-05-19 | Aptamir Therapeutics, Inc. | miRNA modulators of thermogenesis |
| WO2013181613A1 (en) * | 2012-05-31 | 2013-12-05 | Research Development Foundation | Mirna for the diagnosis and treatment of autoimmune and inflammatory disease |
| WO2013192576A2 (en) * | 2012-06-21 | 2013-12-27 | Miragen Therapeutics | Oligonucleotide-based inhibitors comprising locked nucleic acid motif |
| US9822358B2 (en) * | 2013-10-18 | 2017-11-21 | Beth Israel Deaconess Medical Center | Treatment of cancers with micro-RNA inhibitors |
| CA2935426C (en) * | 2014-01-30 | 2023-07-25 | F. Hoffmann-La Roche Ag | Polyoligomer compound with biocleavable conjugates for reducing or inhibiting expression of a nucleic acid target |
| US20180023081A1 (en) | 2015-02-04 | 2018-01-25 | Bristol-Myers Squibb Company | Lna oligonucleotides with alternating flanks |
| US20180042847A1 (en) * | 2015-03-16 | 2018-02-15 | Duncan ROSS | Method of treatment comprising membrane-enclosed vesicle |
| WO2017187426A1 (en) * | 2016-04-29 | 2017-11-02 | Aptamir Therapeutics, Inc. | Inhibition of mir-22 mirna by apt-110 |
| CN107432933A (en) * | 2017-07-13 | 2017-12-05 | 中南大学湘雅三医院 | Applications of the miR 22 as target site in the chemotherapy sensitizing medicine for preparing carcinoma of urinary bladder |
| WO2019053235A1 (en) * | 2017-09-15 | 2019-03-21 | Genfit | Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis |
| BR112020018705A2 (en) | 2018-03-14 | 2021-01-05 | Beth Israel Deaconess Medical Center | MICROWAVE INHIBITORS 22 |
| WO2019217907A1 (en) * | 2018-05-11 | 2019-11-14 | The Regents Of The University Of California | Methods and compositions for the treatment of hepatic and metabolic diseases |
-
2019
- 2019-03-14 BR BR112020018705-4A patent/BR112020018705A2/en not_active Application Discontinuation
- 2019-03-14 BR BR112020018752-6A patent/BR112020018752A2/en not_active Application Discontinuation
- 2019-03-14 AU AU2019234916A patent/AU2019234916A1/en active Pending
- 2019-03-14 KR KR1020207029243A patent/KR20200132920A/en unknown
- 2019-03-14 JP JP2020549635A patent/JP2021518841A/en active Pending
- 2019-03-14 US US16/979,782 patent/US11499152B2/en active Active
- 2019-03-14 EP EP19768368.3A patent/EP3765619A4/en active Pending
- 2019-03-14 CA CA3093572A patent/CA3093572A1/en active Pending
- 2019-03-14 KR KR1020207029242A patent/KR20200131287A/en unknown
- 2019-03-14 CN CN201980032204.4A patent/CN112119159A/en active Pending
- 2019-03-14 CN CN201980018587.XA patent/CN111918968B/en active Active
- 2019-03-14 CA CA3093844A patent/CA3093844A1/en active Pending
- 2019-03-14 US US16/979,777 patent/US11753639B2/en active Active
- 2019-03-14 SG SG11202008921YA patent/SG11202008921YA/en unknown
- 2019-03-14 WO PCT/US2019/022350 patent/WO2019178410A1/en unknown
- 2019-03-14 WO PCT/US2019/022351 patent/WO2019178411A1/en active Search and Examination
- 2019-03-14 EP EP19768285.9A patent/EP3765610A4/en active Pending
- 2019-03-14 JP JP2020573079A patent/JP7318166B2/en active Active
- 2019-03-14 SG SG11202008925VA patent/SG11202008925VA/en unknown
- 2019-03-14 AU AU2019234917A patent/AU2019234917A1/en active Pending
- 2019-03-14 RU RU2020132725A patent/RU2020132725A/en unknown
- 2019-03-14 RU RU2020131372A patent/RU2020131372A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2020131372A (en) | 2022-04-14 |
| CA3093572A1 (en) | 2019-09-19 |
| US20210017520A1 (en) | 2021-01-21 |
| JP2021518841A (en) | 2021-08-05 |
| US20210017521A1 (en) | 2021-01-21 |
| CN111918968B (en) | 2023-11-24 |
| EP3765610A4 (en) | 2022-01-19 |
| AU2019234917A1 (en) | 2020-10-01 |
| CN112119159A (en) | 2020-12-22 |
| BR112020018752A2 (en) | 2021-01-05 |
| CA3093844A1 (en) | 2019-09-19 |
| KR20200132920A (en) | 2020-11-25 |
| EP3765619A4 (en) | 2021-12-08 |
| JP7318166B2 (en) | 2023-08-01 |
| US11753639B2 (en) | 2023-09-12 |
| JP2021518159A (en) | 2021-08-02 |
| RU2020132725A (en) | 2022-04-15 |
| WO2019178410A1 (en) | 2019-09-19 |
| KR20200131287A (en) | 2020-11-23 |
| EP3765619A1 (en) | 2021-01-20 |
| US11499152B2 (en) | 2022-11-15 |
| BR112020018705A2 (en) | 2021-01-05 |
| EP3765610A1 (en) | 2021-01-20 |
| AU2019234916A1 (en) | 2020-10-15 |
| SG11202008921YA (en) | 2020-10-29 |
| CN111918968A (en) | 2020-11-10 |
| WO2019178411A1 (en) | 2019-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283639A (en) | Kif18a inhibitors | |
| ZA201807865B (en) | Formulations of an lsd1 inhibitor | |
| IL281939A (en) | Inhibitors of vap-1 | |
| EP4069212A4 (en) | Inhibitors of hif-2alpha | |
| IL276813A (en) | Arginase inhibitors | |
| EP3801503A4 (en) | Inhibitors of sarm1 | |
| SG11202008925VA (en) | Inhibitors of micro-rna 22 | |
| EP3906029A4 (en) | Inhibitors of menin-mll interaction | |
| IL277778B (en) | Bcl6 inhibitors | |
| SG10202006699XA (en) | Inhibition of allergic reaction using an il-33 inhibitor | |
| IL281815A (en) | Inhibitors of vap-1 | |
| GB201819126D0 (en) | Inhibitor compounds | |
| IL269695A (en) | Compounds useful as inhibitors of alcat 1 | |
| IL276013A (en) | Pi4kiiibeta inhibitors | |
| GB201708457D0 (en) | Inhibitors of metallo-beta-lactamases | |
| IL276312B1 (en) | Use of alkoxypyrazoles as nitrification inhibitors | |
| EP3801500A4 (en) | Inhibitors of sarm1 | |
| IL281514A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| IL277806A (en) | Growth inhibitor | |
| EP3801525A4 (en) | Inhibitors of prolyl-trna-synthetase | |
| EP3801499A4 (en) | Inhibitors of sarm1 | |
| GB201708451D0 (en) | Inhibitors of metallo-beta-lactamases | |
| IL277869A (en) | Substituted propanamides as inhibitors of nucleases | |
| IL277866B1 (en) | Substituted aminothiazoles as inhibitors of nucleases | |
| IL277578A (en) | Novel salt forms of urat-1 inhibitors |